Antigen-presenting cells (APCs) play a central role in regulation of the innate and adaptive immune responses. 1 APCs have the ability to capture, process, and present antigens through their MHC cell-surface molecules to the T-cell receptor (TCR) to mount an MHC-restricted immune response. [2] [3] [4] [5] [6] APCs include a myriad of immune cells, such as B cells, neutrophils, macrophages, eosinophils, basophils, and dendritic cells (DCs). Among these populations, DCs are considered the major APCs bridging innate and adaptive immune responses. 7, 8 The mode of action of DCs is mediated through at least 3 signals: (1) TCR activation, (2) activation of costimulatory molecules, and (3) secretion of chemokines and proinflammatory cytokines. 8 Indeed, depletion of CD11c 1 DCs has been shown to alter cytotoxic T-lymphocyte responses to infection, as well as CD4
1 T-cell activation and antibody production. 9 In addition, DCs can also regulate innate and adaptive immune responses by recognizing pathogen-associated molecular patterns (PAMPs), such as microbial nucleic acids, lipoproteins, and carbohydrates, or damage-associated molecular patterns (DAMPs) released from injured cells through intracellular or surfaceexpressed pattern recognition receptors (PRRs). [10] [11] [12] [13] [14] Although considered ''atypical'' APCs, Mast cells (MCs) have been described mainly for their role in allergic and autoimmune responses. 15, 16 It is well established that MCs are important effector cells in IgE-mediated allergic inflammation, and MCs are also recognized to influence innate and adaptive immune responses. 8 1 T-cell response to infection and in experimental autoimmune encephalomyelitis (EAE), a mouse model for human multiple sclerosis, suggesting that MCs play a role in mediating T-cell responses. [17] [18] [19] [20] Like DCs, MCs can directly present antigens to T cells in vitro, inducing an antigen-specific clonal expansion of T-cell populations, and are known to express costimulatory molecules and secrete a myriad of chemokines and proinflammatory cytokines. 8, 15, 16, 21 However, MCs express MHC class II intracellularly rather than at the cell surface. 22 Moreover, MCs have been shown to promote T-cell activation in an antigen-independent manner, and no direct evidence has been provided thus far on the capacity of direct antigen presentation to the TCR. 8, 23 Thus the mechanisms by which MCs regulate T-cell responses remain unclear and are yet to be determined.
Recently, we have shown the role of nicotinamide adenine dinucleotide (NAD 1 ), a cofactor found in all living cells and nutrients, in T-cell fate regulation. 24 , 25 We have demonstrated that NAD 1 was able to regulate CD4 1 T-cell differentiation through a novel pathway that is independent of the cytokine environment and well-established transcription factors. 25 More recently, we have reported the unique immunosuppressive properties mediated by NAD 1 through systemic IL-10 cytokine production. 24 Although we characterized the role of NAD 1 in regulating T-cell fate, the precise mechanisms of action remain largely unknown.
Here we show that after NAD 1 administration, MCs are able to induce exclusively CD4
1 T-cell differentiation in vitro and in vivo in the absence of antigen and major APCs. Furthermore, we demonstrate that MC-driven CD4 1 T-cell differentiation was independent of MHC class II or TCR activation. Furthermore, when assessing the functional effect of MC-mediated CD4
1 T-cell differentiation, we observed that treatment with NAD 1 resulted in profound alterations in innate and adaptive immunity and survival outcome after Listeria monocytogenes infection. Collectively, our study unravels a new cellular and molecular pathway regulating innate and adaptive immune responses that is mediated exclusively by MCs.
METHODS

Animals and diphtheria toxin treatment
Eight-to 10-week-old wild-type (WT) C57BL/6 (B6, H2 b ) mice were purchased from Charles River Laboratories (Wilmington, Mass 
Cultivation of bone marrow-derived mast cells
Bone marrow-derived mast cells (BMMCs) from 8-to 10-week-old C57BL/6J WT mice were obtained by culturing bone marrow cells from femurs and tibias. In short, mice were killed by means of cervical dislocation, intact femurs and tibias were removed, and bone marrow cells were harvested by means of repeated flushing with sterile media. BM cells were cultured in WEHI-3-conditioned medium (containing IL-3) for 90 days, at which time the cells were greater than 95% c-Kit high FcεRIa high , as determined by using flow cytometric analysis with PE-Cy7 anti-mouse FcεRIa (clone MAR-1; eBioscience, San Diego, Calif) and ef450 anti-mouse c-Kit/CD117 (clone 2B8; eBioscience, San Diego, Calif).
Human MC line LAD-2 culture
The human MC line LAD-2 was a generous gift from Dr A. Kirshenbaum (National Institutes of Health/National Institute of Allergy and Infectious Diseases). LAD-2 MCs were cultured in serum-free media (StemPro-34 SFM; Life Technologies, Grand Island, NY) supplemented with 2 mmol/L L-glutamine, 100 U/mL penicillin, 50 mg/mL streptomycin, and 100 ng/mL recombinant stem cell factor. LAD-2 cells were tested periodically for expression of Kit and FcεRI by using flow cytometry.
Cell culture
Isolated naive CD4
1 T cells or CD11c 1 DCs (1 3 10 6 cells per well) were cultured in 48-well flat-bottom plates in 0.5 mL of complete RPMI 1640 medium supplemented with 10% FCS, 200 mmol/L L-glutamine, 100 U/mL penicillin/streptomycin, and 4.5 g/L glucose in the presence of 10 mg/mL plate-bound anti-mouse a-CD3 (17A2) and 2 mg/mL soluble a-CD28 (37.51 
Flow cytometry
Fluorescence-labeled anti-mouse CD4 (clone GK1.5), CD11b (M1/70), CD11c (N418), CD41 (eBioMWReg30), CD61 (2C9. G3), IL-1b (NJTEN3), IL-4 (11B11), IL-6 (MP5-20F3), IL-10 (JES5-16E3), IL-12/IL-23p40 (C 17.8), IL-17 (eBio17B7), IFN-g (XMG 1.2), latency-associated peptide (TW7-16B4), and TNF-a (MP6-XT22) were obtained from eBioscience. All antibodies were used at a concentration of 2 to 5 mg per 1 3 10 6 cells. To set the gates, flow cytometric dot plots were based on comparison with isotype controls, fluorescence minus one, and permeabilized and unpermeabilized unstained cells. Intracellular staining for IL-1b, IL-4, IL-6, IL-10, IL-12/IL23p40, IL-17, IFN-g, latency-associated peptide, and TNF-a was performed according to the manufacturer's protocols. Cells were fixed and permeabilized with Cytofix/Cytoperm solution (BD Biosciences, San Jose, Calif). Flow cytometry was performed on a BD FACSCanto II (BD Biosciences) by using standard procedures, and data were analyzed with FlowJo software (TreeStar, Ashland, Ore).
ELISA
Mouse IL-4, IL-17A, and IFN-g levels were measured with commercial kits (eBioscience), as described previously. 24, 25 RNA extraction and quantitative PCR BMMCs from C57BL/6 mice were cultured in the presence of NAD 1 (500 mmol/L), LPS, or placebo (PBS). After 24 hours of culture, cells were collected, and mRNA was extracted by using the RNAqueous extraction kit, according to the manufacturer's protocols (Applied Biosystems, Foster City, Calif). Briefly, cells were homogenized in lysis buffer (total volume of 0.5 mL) and passed through a column. After successive washes, RNA was eluted. For real-time PCR reactions, IL-1a (Mm00439620_m1), IL-b (Mm01336189_m1), IL-4 (Mm00445259_m1), IL-6 (Mm004446190_m1), IL-10 (Mm00439616_m1), IL-12a (Mm00434165_m1), IL-23 (Mm00 518984_m1), TGF-b 1 (Mm01178820_m1), TNF-a (Mm00443260_g1), TLR2 (Mm00442346_m1), TLR4 (Mm00445273_m1), CD86 (Mm00 444543_m1), CD80 (Mm00711660_m1), inducible costimulator ligand (Mm00497237_m1), OX40 ligand (Mm00437214_m1), and IL-33 (Mm00 505403_m1) measurements were performed with TaqMan primers and probes from Applied Biosystems. The housekeeping gene glyceraldehye-3-phosphate dehydrogenase (Mm99999915_g1) was used as a control. by using flow cytometry (Fig 1, C) and ELISA (Fig 1, D) , respectively. Statistics were as follows: n 5 15 (Fig 1, A and B) or n 5 10 (Fig 1, C and D) . Data were derived from 3 independent sets of experiments. The Student t test and ANOVA were used accordingly to compare groups: **P < .01 and ***P < .001. Data are presented as means 6 SDs. FACS, Fluorescein-activated cell sorting; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
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RNA sequencing analysis
BMMCs from C57BL/6 mice were cultured in the presence of NAD 1 (500 mmol/L), LPS (10 mg/mL; Escherichia coli O127:B8), or placebo (PBS). After 16 hours of culture, cells were collected and RNA was extracted with the RNAqueous extraction kit, according to the manufacturer's protocols (Applied Biosystems), as described above. cDNA was obtained by using New England Biolabs kits (NEBNext Ultra Directional RNA Library Prep Kit for Illumina; New England Biolabs, Ipswich, Mass). Briefly, mRNAwas extracted with polyT magnetic beads, and then first-and second-strand syntheses were performed. Once double-strand cDNA was generated, DNA was cleaned up with magnetic beads and then went into library prep. Library preparation was performed by ligating on the P5 and P7 Illumina adaptors along with an index and amplifying the sequencing library by using PCR. The final library was cleaned up by using magnetic beads and made ready for sequencing. FastQ files were aligned against the Ensembl GRCm38.75 genome by using the STAR aligner (version 2.3.1z4) with default parameters. 28 Alignment files (BAM format) were filtered to retain only primary alignments (Samtools view-F 0x0100) and inspected for duplication rate with Picard tools MarkDuplicates; for downstream analyses, duplicate reads were not removed because of the high-quality input RNA. 29 Reads were quantified at the gene level by using featureCounts with annotated exon features in the Ensembl GRCm38.75 GTF file. 30, 31 The resulting count matrix was normalized and analyzed for differential expression with DESeq2 software. Ingenuity Pathways Analysis (Ingenuity Systems, Redwood City, Calif) applications were used to generate canonical pathways.
Statistical analysis
Data are presented as means 6 SDs. Statistical analysis was done with the 2-tailed Student t test (between 2 groups) and 1-way ANOVA (among multiple groups), where appropriate. Survival was compared by using the log-rank test. P values of less than .05 were considered statistically significant.
Study approval
Animal care and use were in accordance with the National Institutes of Health and Institutional Animal Care and Use Committee guidelines.
RESULTS
NAD
1 requires an intermediary signal to promote
We have demonstrated previously that NAD 1 regulated CD4 
IL-17A
1 T-cell frequencies were evaluated by using flow cytometry. Data indicated that NAD 1 administration was sufficient to promote a significant increase in frequencies of CD4
1 IL-4
1
, and CD4
T cells in vivo (Fig 1, A) . Of note, NAD 1 administration to Rag2 2/2 mice adoptively transferred with naive CD4 1 T cells from Rag 5C.C7 transgenic mice promoted CD4
1 IFN-g 1 T-cell differentiation in the absence of moth cytochrome C peptide challenge (Fig 1, B) . Thus we next assessed in vitro whether NAD 1 directly promotes CD4
1 T-cell differentiation and cytokine production. 1 T cells were assessed for IFN-g, IL-4, and IL-17 production by using flow cytometry and ELISA. Consistent with our previous reports, flow cytometry revealed that NAD 1 promotes a robust increase of CD4 1 IFN-g 1 Tcell frequencies after TCR activation, particularly in the presence of IL-2 (Fig 1, C) . These findings were confirmed by means of ELISA, indicating increased IFN-g, IL-4, and IL-17 production after CD3/CD28 activation (Fig 1, D) . Of note, the highest CD4 
CD11c
1 DCs were cultured in the presence of 1 mg/mL LPS. After 16 hours, cells were collected and cytokine expression was quantified by using real-time PCR. Consistent with numerous reports, stimulation of CD11b 1 CD11c 1 cells by LPS resulted in increased mRNA expression levels of IL-1a, IL-1b, IL-6, IL-23, and TNF-a but not IL-12 and a downregulation of TLR4. 33, 34 More importantly, in the presence of NAD 1 , CD11c 1 CD11b 1 DCs exhibited increased mRNA expression levels of IL-1a, IL-1b, IL-6, IL-10, IL-12, IL-23, TGF-b1, TNF-a, TLR2, and TLR4 in a dosedependent manner (see Fig E1, 
CD11b
1 DC activation in vivo as well. C57BL/ 6 WT mice were treated daily with 40 mg of NAD 1 or PBS by means of intraperitoneal injection. Consistent with our in vitro findings, we found that NAD 1 -treated WT mice showed increased cytokine production, including IL-1b, IL-4, IL-6, IL-10, IL-12, TGF-b1, and TNF-a, by CD11b 
CD11c
1 cells when compared with levels in PBS-treated WT mice (Fig 2) . This is consistent with a previous study indicating that FIG 
1 DCs, we tested whether CD4 1 T-cell differentiation resulted from NAD 1 -mediated DC activation. As reported by us and others, 26, 27 more than 99% of professional phagocytes, including both DCs and macrophages, were depleted in WT mice by means of injection of clodronate liposomes (see Fig E2, A, in this article's Online Repository at www.jacionline.org). As shown in Fig E2, 
IL-4
1 , and CD4
1 IL-17 1 differentiation (see Fig E3, (Fig 3) .
Therefore we next sought to dissect the role of MCs in NAD 1 -mediated T-cell differentiation in vitro. BMMCs were generated, as described in the Methods section. The average yield of MCs (FcεRI 1 c-Kit 1 double-positive cells) increased with time and reached greater than 95% on day 90, as shown by using flow cytometry (see Fig E3, C) . BMMCs were cultured over 6 weeks to express homogenous levels of KIT and FcεRI. 8 BMMCs were then directly cocultured with naive CD4
1
CD44
2
CD62L
1 T cells in the presence of NAD 1 or PBS. Moreover, MCs and T cells were cocultured in separate compartments by using a transwell system to determine whether these cells require cell-cell contact. As an additional control, naive CD4 
1 T cells were cocultured in the presence of NAD 1 and T cells were activated with a-CD3/a-CD28, frequencies of CD4 1 IFN-g 1 and CD4
1 IL-17 1 T cells increased further (see Fig E4) . These results were consistent with our initial findings indicating that cultured naive CD4 (Fig 1, C and D) . Like DCs, MCs express costimulatory molecules and secrete a myriad of cytokines that are known to regulate innate and adaptive immune responses. Thus to determine whether MCs mediate CD4
1 T-cell differentiation through costimulatory molecules, cytokines, or both, MCs were treated with NAD 1 in vitro, and mRNA levels of OX40 ligand, inducible costimulator ligand, CD80, CD86, TNF-a, IL-4, IL-6, and IL-33 were measured by using real-time PCR. NAD 1 induced a modest increase in CD80 and IL-33 and a decrease in IL-4 mRNA expression levels by MCs (see Fig E5, A, in this article's Online Repository at www.jacionline.org). It is well established that CD80 can either promote or inhibit activation of naive T cells by binding to CD28 or cytotoxic T lymphocyte-associated antigen 4, respectively. Therefore to assess the role of CD80 in NAD 1 -MC-mediated CD4 1 T-cell differentiation, blockade of CD80 with a neutralizing antibody was performed in vitro by using our cell-cell contact coculture system. Our findings indicated that CD80 blockade did not reduce CD4
IL-17
1 T-cell frequencies when compared with an isotype control (see Fig E5, B and C) . Of note, CD80 blockade resulted in increased CD4 1 
IL-4
1 T-cell frequencies (see Fig E5, D) , suggesting that CD80 can play an inhibitory effect on MCmediated IL-4 cytokine production. Collectively, our findings suggest that MC-mediated CD4 1 T-cell differentiation does not require cell-cell contact or involvement of conventional costimulatory molecules, such as CD80.
MC-mediated CD4
1 T-cell differentiation is conserved in the human MC line LAD-2
We next investigated whether this novel pathway is conserved in human subjects and whether human MCs could regulate human CD4 1 T-cell differentiation as well. Naive CD4 1 T cells were isolated from healthy donors and cocultured in direct contact or in our transwell system with LAD-2 cells, a well-established human MC line. Similar to murine BMMCs, cocultures were performed in the presence of NAD 1 or PBS and with or without a-CD3/a-CD28. Flow cytometry indicated that in the presence of NAD 1 , human MCs promoted CD4
1 IFN-g 1 T-cell differentiation (see Fig E6, A, in this article's Online Repository at www.jacionline. org). Consistent with our murine BMMC data, human MCs were able to promote T H 1 polarization in the absence of cellcell contact. Taken together, these results suggest that the MCmediated CD4
1 T-cell differentiation pathway through MCs is conserved in human subjects as well. , LPS, or PBS. As shown in Fig 4, A, the results indicated that NAD 1 significantly upregulated 603 genes and downregulated 753 genes (with a P value of less than .05) when compared with MCs treated with PBS. Moreover, when compared with LPS conditions, changes in the number of genes marked as differentially expressed were dramatic. When comparing LPS versus NAD 1 conditions, 6053 genes were significantly upregulated, and 5845 were found to be downregulated, suggesting that NAD 1 signaling machinery is distinct from LPS stimulation. As expected, dramatic changes in gene expression were observed when comparing PBS with LPS treatment (Fig 4, A) .
To elucidate potential genes involved in MC-mediated CD4
1
T-cell differentiation, we investigated the role of the most upregulated genes in NAD 1 versus PBS conditions and compared them with gene expression characteristics in presence of LPS (Fig 4, B) . 
CD4
1 IL-4 1 , and CD4 1 IL-17A 1 cells were assessed by using flow cytometry. Data were derived from 2 independent experiments (n 5 5-10). Data represent means 6 SDs. ANOVA was used to compare groups: ***P < .001. APC, Allophycocyanin; PE, phycoerythrin. Among the first 10 genes upregulated in PBS versus NAD 1 conditions, a robust upregulation of autotaxin (Enpp2), dystrophia myotonica protein kinase (DMPK), and FERM domain containing 5 (Frmd5) were specific to NAD 1 conditions when compared with PBS or LPS treatment. Both DMPK 38, 39 and FRMD5 40 proteins have been implicated in stabilizing cell membranes and cytoskeletons. Autotaxin has been shown to play a role in T-cell activation and chemotaxis, 41, 42 and MCs have been shown to be able to produce autotaxin. 43 Furthermore, Ingenuity Pathway Analysis predicted significant perturbations by NAD 1 of other signaling molecules involved in MC activation, such as TNFAIP2 or IKBKG (NEMO ; Fig 4, C) . It is well established that the ectoenzyme autotaxin generates lysophosphatidic acid (LPA), a potent lipid mediator that acts on a series of specific G proteincoupled receptors through hydrolysis of lysophosphatidylcholine. 41 LPA can be produced by a myriad of different cell types that include postmitotic neurons, adipocytes, MCs, and other lymphoid cells. Autotaxin has been recently described as regulating cytokine production, and autotaxin-LPA pathways have been shown to play a critical role in asthmatic patients. 44 Both human and murine T cells express LPA receptors, 45, 46 and LPA has been found to inhibit TCR-mediated calcium mobilization. 47 Collectively, our results indicate that MC activation by NAD 1 triggers a unique gene expression profile that is distinct from LPS stimulation and suggests the existence of an alternative pathway that remains to be determined. Fig E6, B) .
MCs induce T-cell differentiation in MHC class II
In addition, WASP 2/2 mice, which are known to have an altered TCR activation and cytokine production, in particular IFN-g, 48 were used to assess the role of TCR in NAD 
IL-17
1 T-cell frequencies in WASP 2/2 mice when compared with the control group (see Fig E6, C) . Collectively, our results suggest that NAD 1 -MC-mediated CD4 1 T-cell differentiation is functional, even in the absence of MHC class II or with altered TCR activation.
Daily NAD
1 treatment protects against lethal doses of L monocytogenes through MCs exclusively WT mice were pretreated for 5 consecutive days with NAD 1 before infection with a nonlethal dose of L monocytogenes to test whether regulation of innate and adaptive immune cells through MCs after NAD 1 administration had a physiologic effect.
In addition, a control group of animals was pretreated with PBS before infection. Mice treated with PBS had only a modest loss of weight, did not exhibit signs of lethargy or gained weight 7 days after infection, and showed 100% survival (Fig 5, A) when infected with a nonlethal dose of L monocytogenes. In contrast, mice pretreated with NAD 1 before infection (nonlethal dose) had a more pronounced loss of weight, exhibited lethargy, and were very susceptible to infection with an 80% mortality rate (Fig 5, A) .
Thus showed an 80% survival rate (Fig 5, A) 1 T-cell subsets. Because T H 1 has been shown to play a protective role in L monocytogenes infection, 35 we initially expected NAD 1 pretreatment to protect mice after bacterial infection. However, we could not rule out that continuous NAD 1 treatment might be required to sustain a robust T H 1 response. Thus we assessed whether prolonged and continuous treatment with NAD 1 could provide protection against L monocytogenes infection. As shown in Fig 5, T-cell differentiation through a pathway distinct of wellestablished transcription factors. 25 In addition, we showed that NAD 1 altered dramatically differentiated T H 1 and T H 2 CD4
1
T cells by repressing their cytokine production and transcription factors. 25 More importantly, second stimulation of differentiated T H 1 and T H 2 CD4
1 T cells was profoundly altered when they were cultured in the presence of NAD 1 after first stimulation. 25 Thus we next investigated whether pretreatment with NAD Fig E7, B) , which was consistent with our previous studies. 24, 25 Although CD4 1 IFN-g 1 T-cell responses remained similar in NAD 1 -and placebo-treated mice, continuous treatment with NAD 1 promoted host protection against a lethal dose of L monocytogenes. In addition, NAD 1 affected the regulation and function of other important immune cells, such as MCs and, more importantly, DCs. Thus we investigated whether NAD 1 promotes IFN-g production that is not mediated by CD4 1 T cells. Our results indicated that mice treated with NAD 1 exhibited a significant increase in IFN-g production by non-CD4 1 T cells, suggesting that NAD 1 can promote IFN-g production by other non-CD4 1 lymphocytes (see Fig E7, C) . Taken together, our results indicate that continuous treatment with NAD 1 promotes robust IFN-g production and protects against lethal doses of L monocytogenes through MCs exclusively.
Pretreatment with NAD
1 renders mice susceptible to sublethal doses of L monocytogenes by dampening the MCH class II-TCR pathway Our data indicate that mice pretreated with NAD 1 are susceptible to sublethal doses of L monocytogenes, whereas continuous treatment protects against lethal doses. Thus we next investigated how pretreatment with NAD 1 rendered mice susceptible to a sublethal dose of bacteria.
Because antigen presentation through the MHC class II cellsurface molecule is crucial in CD4 1 T-cell responses and our results indicated that NAD 1 promotes CD4 1 T-cell differentiation in the absence of MHC class II molecules, we investigated the effect of NAD 1 pretreatment on MHC class II expression of CD11b 1 CD11c 1 DCs after L monocytogenes infection. The results indicated that pretreatment with NAD 1 resulted in a dramatic decrease in MHC class II expression when compared with the control group (see Fig E7, D) , indicating that NAD dampens antigen presentation capacities of DCs after L monocytogenes infection. WT mice pretreated for 5 consecutive days with NAD 1 before infection with a nonlethal dose of L monocytogenes had a more pronounced loss of weight, exhibited lethargy, and were very susceptible to infection with an 80% mortality rate (Fig 5, A) . In contrast, WT mice continuously treated with NAD 1 exhibited resistance (>60% survival rate) to even lethal doses of L monocytogenes when compared with the control group of mice that exhibited a 100% mortality rate (Fig 5, B) .
Collectively, our results indicate that pretreatment with NAD 1 will trigger the NAD 1 -MC pathway while dampening the APC-MHC class II-TCR signaling machinery, suggesting that discontinuous administration of NAD 1 can subject the animals to an immunodeficient state that renders them susceptible to sublethal doses of L monocytogenes. Collectively, our results indicate that NAD 1 profoundly alters, in the absence of antigen, innate and adaptive immune responses through MCs exclusively and independently from the classical DC/MHC class II antigen presentation machinery that results in significant physiologic changes (Fig 6) .
DISCUSSION
Our previous studies have demonstrated a novel role for NAD 1 in regulating T-cell fate in the context of antigen-specific responses. 24, 25 However, whether NAD 1 mechanisms of action operate in an antigen-independent manner and whether NAD 1 affects other immune cells remained unknown. APCs, in particular DCs, have been considered the most potent immune cells to prime naive CD4 1 T cells. In addition to their capacity for antigen processing and presentation to the TCR through MHC class II cell-surface molecules, DCs can regulate CD4
1 T-cell activation through costimulatory molecules and a myriad of secreted cytokines and chemokines. 8 Moreover, it has been reported that recognition of conserved PAMPs, such as microbial nucleic acids, lipoproteins, and carbohydrates, or DAMPs, which are released from injured, through intracellular or distinct PRRs expressed on DCs contribute to pathogen-specific CD4 1 T-cell responses. 12 Thus DCs and antigen presentation are regarded as fundamentally required and play a central role in CD4 1 T-cell activation and differentiation and are considered the bridge between innate and adaptive immune responses. 1, 7, 8, 49 These observations are widely supported by studies based on transgenic animals with alteration in MHC class II, TCR, and DC depletion and confirmed in immunodeficient patients. 50, 51 Here we demonstrated that NAD 1 , a natural cofactor, induces CD4
1 differentiation in the absence of antigen presentation, MHC class II expression, and absence of TCR activation. Furthermore, we demonstrate that effects of NAD 1 are not mediated by major APCs, including DCs, but through MCs exclusively. Moreover, our study indicated that major costimulatory molecules are not involved in NAD 1 -MC-mediated CD4 1 T-cell differentiation, suggesting that MCs deliver T-cell stimulation through an alternative pathway. This is in line with previous studies indicating that MCs cannot prime naive CD4
1 T cells, most likely because of an altered costimulatory molecule expression. 8 Furthermore, previous studies have reported that MCs express MHC class II molecules; however, it has been found to be sequestered mainly in lysosomal intracellular compartments. 22 This is consistent with our findings indicating that NAD 1 -MC-mediated CD4 1 T-cell differentiation does not require antigen presentation or MHC class II molecules.
The cofactor ATP is well recognized for its role as a source of high energy and in cellular metabolism; however, when released from cells after cellular damage, ATP acts as a DAMP signal. DAMP signaling is mainly mediated through the PRRs that are expressed on APCs, in particular DCs and macrophages. 52 Although the primary function of PRRs is to mediate innate immune responses to pathogen invasion and tumors, increasing evidence has shown their role in the development of autoimmune and chronic inflammation 52 , which is also a cofactor, has been described for its role in energy metabolism and more recently in aging. [54] [55] [56] In contrast to ATP, NAD 1 -mediated innate and adaptive immune regulation was intermediated by MCs and was independent of major APCs, including DCs and macrophages. Moreover, our previous studies have underscored the robust immunosuppressive properties of NAD 1 by promoting a systemic increase in IL-10 cytokine levels through regulatory type 1 cells. 24, 25 We have also shown that NAD 1 regulates CD4
1 T-cell fate in the absence of major transcription factors. Indeed, NAD 1 was able to promote a robust T H 1 response in the absence of T-bet, a transcription factor considered indispensable for T H 1 differentiation and IFN-g production. 25 In contrast to proinflammatory responses induced by DAMPs, including ATP, NAD 1 protects against autoimmune diseases and promotes allograft survival. 24, 25 Furthermore, our RNA-sequencing analysis indicated that treatment with NAD 1 resulted in upregulation of a distinct set of genes when compared with LPS, a prototypical PAMP, suggesting that NAD 1 triggered a different signaling pathway that remains yet to be determined in detail.
In line with our previous reports, NAD 1 treatment downregulated T-bet expression but did not alter CD4 IL-17A 1 (C) cells were assessed by using flow cytometry (n 5 6). Data were derived from 2 independent experiments. *P < .05, **P < .01, and ***P < .001, as determined by means of ANOVA, comparing the indicated groups. Data represent means 6 SDs. APC, Allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin. (Fig E5, B) , (Fig E5, C) , and CD4 1 IL-4 1 (Fig E5, D) cells were assessed by using flow cytometry (n 5 6).
Data were derived from 2 independent experiments. ns, Not significant. *P < .05, **P < .01, and ***P < .001, as determined by using the Student t test and ANOVA, comparing the indicated groups. Data represent means 6 SDs. APC, Allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
